Fulcrum Therapeutics eliminates COO role; Mel Hayes transitions to EVP, Patient Experience

Fulcrum Therapeutics, Inc.

COO position eliminated effective Oct 2, 2023; no principal operating officer thereafter.
Mel Hayes remains as Executive Vice President, Patient Experience under amended agreement.
New role has 12-month term; compensation and severance unchanged.
Restructuring aimed at streamlining company functions.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Mel Hayes

Executive Vice President, Patient Experience

FULC · Fulcrum Therapeutics, Inc.

Effective: 2023-10-02
Filed: October 2, 2023, 7:59 PM ET

On September 28, 2023, in connection with a decision to streamline certain functions within the company, Fulcrum Therapeutics, Inc., or Fulcrum, notified Mel Hayes, Fulcrum’s current chief operating officer (and principal operating officer) that it was eliminating his position effective October 2, 2023, following which, Fulcrum does not have a principal operating officer. Mr. Hayes agreed to remain with Fulcrum as its Executive Vice President, Patient Experience, and in connection therewith, entered into an amended and restated employment agreement reflecting his new role and title at Fulcrum.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mel Hayes changed role as Executive Vice President, Patient Experience at Fulcrum Therapeutics, Inc..

Role: Executive Vice President, Patient Experience

Exact text from the filing

On September 28, 2023, in connection with a decision to streamline certain functions within the company, Fulcrum Therapeutics, Inc., or Fulcrum, notified Mel Hayes, Fulcrum’s current chief operating officer (and principal operating officer) that it was eliminating his position effective October 2, 2023, following which, Fulcrum does not have a principal operating officer. Mr. Hayes agreed to remain with Fulcrum as its Executive Vice President, Patient Experience, and in connection therewith, entered into an amended and restated employment agreement reflecting his new role and title at Fulcrum.

View on SEC.gov

Fulcrum Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-249011

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.